Ion Beam Applications (IBA): Protect, enhance and save lives
Belgium, December 2011. Life had been anything but tranquil at IBA since its creation in 1986. From research lab with a focus on particle physics to premier producer of a new generation of cyclotrons for industrial use, it had also applied its unique skills to fields as diverse as sterilization, dosimetry, the production of radioisotopes for medical applications and finally offered turnkey solutions for Proton Therapy (PT). In the process, it had pretty much tested every concept in the financial dictionary, including a management buyout, an IPO and subsequent secondary offerings, various categories of public and private investors, carve-outs and spin-outs, not to mention market consolidations and build-ups. What emerged in 2011 was a world leader in cancer treatment, in particular in the leading edge proton therapies, with over 2,100 employees and almost €200 million in sales in the first half of 2011, EBIDA of €13.6 million, and €5 million in profit before taxes. As per the 2011 letter from management, it achieved this feat by “… daring to create innovative and superior science to detect and treat cancer.” But challenges remained. First of all, the PT business, while profitable, required constant investments to remain on top. Pencil Beam Scanning (PBS) was introduced commercially in 2009 but other expensive developments would be required soon. The pharma business, which focused on molecular imaging, also faced massive investments for phase III trials of new molecules. Analysts were clearly struggling with the immensely different nature and cycles of these two lines of business, which muddled IBA’s financial results and ultimately affected the share price. Finally, succession challenges were looming in top management, with the chief research officer (CRO) approaching retirement age and CEO Pierre Mottet having spent the last 24 years in the company.
Managing high tech developments, life science applications, positioning a technology, segmenting, growth management, IPO, buyout, carve-out, nuclear physics, proton therapies, cancer treatment.
Ion Beam Applications, Healthcare, Healthcare, Medical Equipment
December 2011
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
The China Resources Beer (CR Beer) case study is a compelling narrative of the world’s largest beer producer by volume under the leadership of CEO Hou Xiaohai. In 2016 CR Beer embarked on a pivotal transformation journey. This case study offers cr...
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 5 February 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 3 February 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD Brain Circuits 28 January 2025
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 28 January 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications